Robert Richard, Ph.D. Appointed Vice President of Research and Development at Anika Therapeutics

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced the appointment of Robert Richard, Ph.D., to the newly created position of Vice President of Research and Development.

Dr. Richard is a 20-year research and development (R&D) veteran bringing extensive leadership and product development experience in orthopedic and regenerative medicine. In this new role, Dr. Richard will oversee the Company’s global R&D function and the development of the Company’s novel product offerings from concept through commercialization.

“We are delighted to strengthen our R&D expertise and our executive leadership team with the addition of Dr. Richard, as we continue Anika’s ongoing transformation into a global commercial organization,” said Joseph Darling, President and Chief Executive Officer of Anika Therapeutics. “His depth of knowledge and experience will help us to accelerate and advance our orthopedic and regenerative medicine pipeline and leverage the broad utility of our technology platform.”

“I am excited to lead Anika’s R&D function during its next phase of innovative growth,” said Robert Richard, Ph.D., Vice President of Research and Development at Anika Therapeutics. “Anika has the resources to deliver a cascade of innovative treatments to patients over the next several years and I look forward to working with this talented R&D organization and management team.”

Dr. Richard has previously held leadership positions with C.R. Bard, Boston Scientific, and Johnson & Johnson, where he led R&D organizations through numerous product development initiatives from the conceptual phase through commercialization. While leading R&D at the surgical division at C.R. Bard, Dr. Richard led programs that launched over 20 new products based on advanced biomaterials technologies over a ten-year period.

Most recently, he led the R&D organization at Hyalex Orthopaedics, an early-stage medical device company advancing treatments based on a novel polymer technology that mimics cartilage. He holds a Ph.D. in polymer chemistry and plastics engineering from the University of Massachusetts Lowell as well as bachelor of science degrees in chemistry and biology from the University of Massachusetts Dartmouth. Dr. Richard is a named inventor on 38 U.S. patents and currently has 19 U.S. patent applications pending. Click here to view Dr. Richard’s full bio.




Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.